Cargando…
Risk Factors and Outcomes for Multidrug Resistant Pseudomonas aeruginosa Infection in Immunocompromised Patients
Background: Pseudomonas aeruginosa (PSA) infection often occurs in immunocompromised patients, which also face an increased risk of multidrug-resistant (MDR) bacteria. A deeper knowledge of the risk factors for MDR-PSA infection in this patient population may help to choose appropriate empirical ant...
Autores principales: | Hernández-Jiménez, Pilar, López-Medrano, Francisco, Fernández-Ruiz, Mario, Silva, J. Tiago, Corbella, Laura, San-Juan, Rafael, Lizasoain, Manuel, Díaz-Regañón, Jazmín, Viedma, Esther, Aguado, José María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686626/ https://www.ncbi.nlm.nih.gov/pubmed/36358114 http://dx.doi.org/10.3390/antibiotics11111459 |
Ejemplares similares
-
2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
por: Elabor, Abdulrahman, et al.
Publicado: (2018) -
VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain
por: Viedma, Esther, et al.
Publicado: (2012) -
Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone
por: Viedma, Esther, et al.
Publicado: (2013) -
Presence of Chromosomal crpP-like Genes Is Not Always Associated with Ciprofloxacin Resistance in Pseudomonas aeruginosa Clinical Isolates Recovered in ICU Patients from Portugal and Spain
por: Hernández-García, Marta, et al.
Publicado: (2021) -
Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)